Status:
UNKNOWN
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
Lead Sponsor:
Phramongkutklao College of Medicine and Hospital
Conditions:
Drug Resistance
Carbapenem-Resistant Enterobacteriaceae Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the treatment outcomes in patients with CRE infections.
Detailed Description
Antibiotic resistance is one of the major problems because of global burden. Resistant pathogens are non-susceptible to available antibiotics, causing of high clinical mortality (clinical impact) and ...
Eligibility Criteria
Inclusion
- Any patients are diagnosed any diseases caused by CRE infection by physicians at Phramongkutklao hospital during 1/4/2018 to 30/4/2021.
- Any patients are more than 18 years old.
- Any patients have at least 1 criterion as following 3.1 Any patients have at least 2 of the signs and symptoms of Systemic inflammatory response syndrome (SIRS), including
- Fever (temperature \> 38 °C) or hypothermia (temperature \< 36°C)
- Tachypnea (heart rate \> 90 beats per minute)
- Respiratory rate \> 20 beats per minute or Paco2 \< 32 mm Hg (4.3 kPa)
- White blood cell count \> 12,000 cells per millilitre (leukocytosis) or \< 4,000 cells per milliliter (leukopenia) 3.2. Any patients are diagnosed with sepsis or have ≥ 2 points of Sequential Organ Failure Assessment (SOFA) Score or qSOFA (Quick SOFA) Score.
- 3. Any patients are diagnosed with septic shock or are received vasopressors (eg, dopamine, norepinephrine, epinephrine, vasopressin, phenylephrine), mean arterial pressure (MAP) \< 65 mm Hg, and lactate \> 2 mmol/L (18 mg/dL) 3.4 Any patients are received mechanical ventilation 3.5 Any patients are admitted at ICU ward.
Exclusion
- Patients are breast-feeding or pregnancy.
- Patients are insufficient or incomplete information on the medical electronic record such as patients transferred.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2021
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT04516395
Start Date
September 1 2020
End Date
April 1 2021
Last Update
August 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Phramongkutklao hospital
Bangkok, Thailand, 10400